EGFR and infection: Confirmatory data also come from trials with unapproved agents, as these were excluded from both the Qi and Funakoshi analyses, but similar effects have been described, including a 14% rate of infection after therapy with the humanized anti-EGFR-antibody zalutumumab [11,12].